Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine

This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial. The study will include healthy adults between the ages of 18 and 65. Participants will be randomly assigned to receive either the Hia vaccine or a placebo. The main goals of the study are to determine safety and measure immune response as it relates to protection against Hia.

NCT Number	NCT07743008
Lead Sponsor	InventVacc Biologicals Inc. Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Dalhousie University, Canadian Center for Vaccinology, Canadian Immunization Research Network
Conditions	Haemophilus Influenzae, Haemophilus Influenzae Type a
Enrollment	47 participants
Start Date	2026-04-29
Primary Completion	2027-02-03 (estimated)
Study Completion	2027-02-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-03